Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cyclo Therapeutics, Inc.CYTH · Entity 82635 | Director | February 27, 2025 | February 28, 2025 |
| VISA INC.V · Entity 495 | Director | November 19, 2015 | November 23, 2015 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cyclo Therapeutics, Inc.
Report date February 27, 2025 · Filed February 28, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 173,966 |
Reported balance
After 2025-02-27 transaction · row 1
1 source rowRow 1 · 2025-02-27 · Grant · Acquired 25,140 · Balance 173,966 F1: Represents the grant of fully-vested shares of common stock that the Reporting Person elected to receive in lieu of cash compensation under the issuer's non-employee director compensation policy. Grant reflects director compensation for the fourth quarter of 2024 and from January 1, 2025 through March 25, 2025. The number of shares received in lieu of cash was calculated based on the closing price of $0.77 per share of common stock on February 26, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the grant of fully-vested shares of common stock that the Reporting Person elected to receive in lieu of cash compensation under the issuer's non-employee director compensation policy. Grant reflects director compensation for the fourth quarter of 2024 and from January 1, 2025 through March 25, 2025. The number of shares received in lieu of cash was calculated based on the closing price of $0.77 per share of common stock on February 26, 2025.
VISA INC.
Report date November 19, 2015 · Filed November 23, 2015
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 2,880 |
Reported balance
After 2015-11-19 transaction · row 1
1 source rowRow 1 · 2015-11-19 · Exercise / conversion · Acquired 2,880 · Balance 2,880 F1: Each restricted stock unit represents a contingent right to receive one share of Visa Inc. common stock or a cash equivalent of its value. The restricted stock units vest on the first anniversary of the date of grant, subject to earlier vesting in full in limited circumstances specified in the award agreement. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2015-11-19 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2015-11-19 · Exercise / conversion · Disposed 2,880 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of Visa Inc. common stock or a cash equivalent of its value. The restricted stock units vest on the first anniversary of the date of grant, subject to earlier vesting in full in limited circumstances specified in the award agreement. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 2,246 |
Reported balance
After 2015-11-19 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2015-11-19 · Grant · Acquired 2,246 · Balance 2,246 F1: Each restricted stock unit represents a contingent right to receive one share of Visa Inc. common stock or a cash equivalent of its value. The restricted stock units vest on the first anniversary of the date of grant, subject to earlier vesting in full in limited circumstances specified in the award agreement. |
| Class A Common StockSEC Table I · non-derivative | IndirectWilliam Shanahan Revocable Trust | 169,580 |
Reported balance
Holding disclosure · report date 2015-11-19 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 169,580 F2: Since the date of the reporting person's last ownership report, 3,548 shares which were previously held directly were transferred to the William Shanahan Revocable Trust, of which Mr. Shanahan is the sole trustee and beneficiary. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of Visa Inc. common stock or a cash equivalent of its value. The restricted stock units vest on the first anniversary of the date of grant, subject to earlier vesting in full in limited circumstances specified in the award agreement.
F2: Since the date of the reporting person's last ownership report, 3,548 shares which were previously held directly were transferred to the William Shanahan Revocable Trust, of which Mr. Shanahan is the sole trustee and beneficiary.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 27, 2025 Filed Feb 28, 2025 20:07 UTC | Cyclo Therapeutics, Inc. CYTH · Entity 82635 | GrantCommon Stock | 25,140 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-005774 · rdgdoc.xml · nonDerivative · entry 1 SHANAHAN WILLIAM S · CIK 0001227259 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 173,966 F1 · price: Represents the grant of fully-vested shares of common stock that the Reporting Person elected to receive in lieu of cash compensation under the issuer's non-employee director compensation policy. Grant reflects director compensation for the fourth quarter of 2024 and from January 1, 2025 through March 25, 2025. The number of shares received in lieu of cash was calculated based on the closing price of $0.77 per share of common stock on February 26, 2025. Read SEC document |
| November 15, 2024 Filed Nov 18, 2024 14:10 UTC | Cyclo Therapeutics, Inc. CYTH · Entity 82635 | GrantCommon Stock | 15,145 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-035587 · rdgdoc.xml · nonDerivative · entry 1 SHANAHAN WILLIAM S · CIK 0001227259 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 148,826 F1 · price: Represents the grant of fully-vested shares of common stock that the Reporting Person elected to receive in lieu of cash compensation under the issuer's non-employee director compensation policy. Grant reflects director compensation for the third quarter of 2024. The number of shares received in lieu of cash was calculated based on the closing price of $0.66 per share of common stock on November 14, 2024. Read SEC document |
| August 16, 2024 Filed Aug 20, 2024 13:50 UTC | Cyclo Therapeutics, Inc. CYTH · Entity 82635 | GrantCommon Stock | 7,937 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-027332 · rdgdoc.xml · nonDerivative · entry 1 SHANAHAN WILLIAM S · CIK 0001227259 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 133,681 F1 · price: Represents the grant of fully-vested shares of common stock that the Reporting Person elected to receive in lieu of cash compensation under the issuer's non-employee director compensation policy. Grant reflects director compensation for the second quarter of 2024. The number of shares received in lieu of cash was calculated based on the closing price of $1.26 per share of common stock on August 16, 2024. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 17:12 UTC | Cyclo Therapeutics, Inc. CYTH · Entity 82635 | GrantStock Option (Right to Buy) · Derivative | 15,562 | $0.00 Strike: $1.28 | $0.00 |
DisclosureSEC source: 0001437749-24-019352 · rdgdoc.xml · derivative · entry 2 SHANAHAN WILLIAM S · CIK 0001227259 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,562 Underlying: Common Stock · 15,562 shares Expires 2034-06-03 F2 · derivative.exercise_date: The option vests over a one year period in equal quarterly installments. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 17:12 UTC | Cyclo Therapeutics, Inc. CYTH · Entity 82635 | GrantCommon Stock | 7,813 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-019352 · rdgdoc.xml · nonDerivative · entry 1 SHANAHAN WILLIAM S · CIK 0001227259 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,744 F1 · price: Represents the grant of fully-vested shares of common stock that the Reporting Person elected to receive in lieu of cash compensation under the issuer's non-employee director compensation policy. Grant reflects director compensation for the first quarter of 2024. The number of shares received in lieu of cash was calculated based on the closing price of $1.28 per share of common stock on June 3, 2024. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 16:40 UTC | Cyclo Therapeutics, Inc. CYTH · Entity 82635 | GrantCommon Stock | 8,466 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-004378 · rdgdoc.xml · nonDerivative · entry 1 SHANAHAN WILLIAM S · CIK 0001227259 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 117,931 F1 · price: Represents the grant of fully-vested shares of common stock that the Reporting Person elected to receive in lieu of cash compensation under the Issuer's non-employee director compensation policy. Grant reflects director compensation for the fourth quarter of 2023. The number of shares received in lieu of cash was calculated based on the closing price of $1.58 per share of common stock on February 13, 2024. Read SEC document |
| November 28, 2023 Filed Nov 30, 2023 09:06 UTC | Cyclo Therapeutics, Inc. CYTH · Entity 82635 | GrantCommon Stock | 9,982 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-033218 · rdgdoc.xml · nonDerivative · entry 1 SHANAHAN WILLIAM S · CIK 0001227259 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,465 F1 · price: Represents the grant of fully-vested shares of common stock that the Reporting Person elected to receive in lieu of cash compensation under the Issuer's non-employee director compensation policy. Grant reflects director compensation for the third quarter of 2023. The number of shares received in lieu of cash was calculated based on the closing price of $1.34 per share of common stock on November 28, 2023. Read SEC document |
| August 18, 2023 Filed Aug 22, 2023 16:06 UTC | Cyclo Therapeutics, Inc. CYTH · Entity 82635 | GrantCommon Stock | 9,835 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-024416 · rdgdoc.xml · nonDerivative · entry 1 SHANAHAN WILLIAM S · CIK 0001227259 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,483 F1 · price: Represents the grant of fully-vested shares of common stock that the Reporting Person elected to receive in lieu of cash compensation under the Issuer's non-employee director compensation policy. Grant reflects director compensation for the second quarter of 2023. The number of shares received in lieu of cash was calculated based on the closing price of $1.36 per share of common stock on August 18, 2023. Read SEC document |
| May 17, 2023 Filed May 18, 2023 16:39 UTC | Cyclo Therapeutics, Inc. CYTH · Entity 82635 | GrantCommon Stock | 25,971 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-015131 · rdgdoc.xml · nonDerivative · entry 1 SHANAHAN WILLIAM S · CIK 0001227259 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,648 F1 · price: Represents the grant of fully-vested shares of common stock that the Reporting Person elected to receive in lieu of cash compensation under the Issuer's non-employee director compensation policy. Grant reflects director compensation for the fourth quarter of 2022 and first quarter of 2023. The number of shares received in lieu of cash was calculated based on the closing price of 1.03 per share of common stock on May 16, 2023. Read SEC document |
| March 07, 2023 Filed Mar 9, 2023 17:09 UTC | Cyclo Therapeutics, Inc. CYTH · Entity 82635 | GrantStock Option (Right to buy) · Derivative | 3,350 | $0.00 Strike: $1.28 | $0.00 |
DisclosureSEC source: 0001437749-23-006003 · rdgdoc.xml · derivative · entry 1 SHANAHAN WILLIAM S · CIK 0001227259 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,350 Underlying: Common Stock · 3,350 shares Expires 2033-03-07 F1 · derivative.exercise_date: The option vests over a one year period in equal quarterly installments. Read SEC document |
| August 27, 2021 Filed Aug 31, 2021 14:41 UTC | Cyclo Therapeutics, Inc. CYTH · Entity 82635 | GrantStock Option (Right to buy) · Derivative | 6,700 | $0.00 Strike: $7.46 | $0.00 |
DisclosureSEC source: 0001437749-21-021240 · rdgdoc.xml · derivative · entry 1 SHANAHAN WILLIAM S · CIK 0001227259 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,700 Underlying: Common Stock · 6,700 shares Expires 2031-08-27 Read SEC document |
| December 11, 2020 Filed Dec 14, 2020 16:02 UTC | Cyclo Therapeutics, Inc. CYTH · Entity 82635 | PurchaseWarrant to Purchase Common Stock · Derivative | 20,000 | Not disclosed Strike: $5.00 | Not disclosed |
DisclosureSEC source: 0001437749-20-025284 · rdgdoc.xml · derivative · entry 2 SHANAHAN WILLIAM S · CIK 0001227259 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2025-12-11 F1 · price: The reported securities consist of 20,000 "Units" purchased by the reporting person for $5.00 per Unit. Each Unit consists of one share of Common Stock and a warrant to purchase one share of Common Stock. Read SEC document |
| December 11, 2020 Filed Dec 14, 2020 16:02 UTC | Cyclo Therapeutics, Inc. CYTH · Entity 82635 | PurchaseCommon Stock | 20,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-20-025284 · rdgdoc.xml · nonDerivative · entry 1 SHANAHAN WILLIAM S · CIK 0001227259 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,677 F1 · price: The reported securities consist of 20,000 "Units" purchased by the reporting person for $5.00 per Unit. Each Unit consists of one share of Common Stock and a warrant to purchase one share of Common Stock. Read SEC document |
| August 27, 2020 Filed Aug 31, 2020 07:49 UTC | Cyclo Therapeutics, Inc. CTDH · Entity 82635 | PurchaseWarrant to Purchase Common Stock · Derivative | 700,000 | Not disclosed Strike: $0.15 | Not disclosed |
DisclosureSEC source: 0001437749-20-018979 · rdgdoc.xml · derivative · entry 2 SHANAHAN WILLIAM S · CIK 0001227259 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 700,000 Underlying: Common Stock · 700,000 shares Expires 2027-08-27 F1 · price: The reported securities consist of 700,000 "Units" purchased by the reporting person for $0.10 per Unit. Each Unit consists of one share of Common Stock and a warrant to purchase one share of Common Stock. Read SEC document |
| August 27, 2020 Filed Aug 31, 2020 07:49 UTC | Cyclo Therapeutics, Inc. CTDH · Entity 82635 | PurchaseCommon Stock | 700,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-20-018979 · rdgdoc.xml · nonDerivative · entry 1 SHANAHAN WILLIAM S · CIK 0001227259 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,367,660 F1 · price: The reported securities consist of 700,000 "Units" purchased by the reporting person for $0.10 per Unit. Each Unit consists of one share of Common Stock and a warrant to purchase one share of Common Stock. Read SEC document |
| April 24, 2020 Filed Apr 27, 2020 16:04 UTC | Cyclo Therapeutics, Inc. CTDH · Entity 82635 | PurchaseCommon Stock | 1,000,000 | $0.10 | $100,000.00 |
DisclosureSEC source: 0001437749-20-008572 · rdgdoc.xml · nonDerivative · entry 1 SHANAHAN WILLIAM S · CIK 0001227259 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,667,660 Read SEC document |
| September 17, 2019 Filed Sep 18, 2019 17:38 UTC | Cyclo Therapeutics, Inc. CTDH · Entity 82635 | PurchaseCommon Stock | 147,200 | $0.19 | $27,968.00 |
DisclosureSEC source: 0001437749-19-018645 · rdgdoc.xml · nonDerivative · entry 1 SHANAHAN WILLIAM S · CIK 0001227259 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,667,660 Read SEC document |
| September 12, 2019 Filed Sep 13, 2019 14:27 UTC | Cyclo Therapeutics, Inc. CTDH · Entity 82635 | PurchaseCommon Stock | 15,000 | $0.19 | $2,850.00 |
DisclosureSEC source: 0001437749-19-018368 · rdgdoc.xml · nonDerivative · entry 1 SHANAHAN WILLIAM S · CIK 0001227259 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,520,460 Read SEC document |
| September 10, 2019 Filed Sep 11, 2019 13:12 UTC | Cyclo Therapeutics, Inc. CTDH · Entity 82635 | PurchaseCommon Stock | 100,000 | $0.20 | $20,000.00 |
DisclosureSEC source: 0001437749-19-018194 · rdgdoc.xml · nonDerivative · entry 2 SHANAHAN WILLIAM S · CIK 0001227259 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,505,460 Read SEC document |
| September 09, 2019 Filed Sep 11, 2019 13:12 UTC | Cyclo Therapeutics, Inc. CTDH · Entity 82635 | PurchaseCommon Stock | 100,000 | $0.18 | $18,000.00 |
DisclosureSEC source: 0001437749-19-018194 · rdgdoc.xml · nonDerivative · entry 1 SHANAHAN WILLIAM S · CIK 0001227259 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,405,460 Read SEC document |
| September 06, 2019 Filed Sep 9, 2019 15:53 UTC | Cyclo Therapeutics, Inc. CTDH · Entity 82635 | PurchaseCommon Stock | 100,000 | $0.17 | $16,500.00 |
DisclosureSEC source: 0001437749-19-018067 · rdgdoc.xml · nonDerivative · entry 2 SHANAHAN WILLIAM S · CIK 0001227259 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,305,460 Read SEC document |
| September 06, 2019 Filed Sep 9, 2019 15:53 UTC | Cyclo Therapeutics, Inc. CTDH · Entity 82635 | PurchaseCommon Stock | 100,000 | $0.16 | $16,000.00 |
DisclosureSEC source: 0001437749-19-018067 · rdgdoc.xml · nonDerivative · entry 1 SHANAHAN WILLIAM S · CIK 0001227259 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,205,460 Read SEC document |
| May 31, 2019 Filed Jun 3, 2019 14:34 UTC | Cyclo Therapeutics, Inc. CTDH · Entity 82635 | PurchaseWarrant to Purchase Common Stock · Derivative | 800,000 | Not disclosed Strike: $0.30 | Not disclosed |
DisclosureSEC source: 0001437749-19-011244 · rdgdoc.xml · derivative · entry 2 SHANAHAN WILLIAM S · CIK 0001227259 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 800,000 Underlying: Common Stock · 800,000 shares Expires 2024-11-30 F1 · price: The reported securities consist of 800,000 "Units" purchased by the reporting person for $0.25 per Unit. Each Unit consists of one share of Common Stock and a warrant to purchase one share of Common Stock. Read SEC document |
| May 31, 2019 Filed Jun 3, 2019 14:34 UTC | Cyclo Therapeutics, Inc. CTDH · Entity 82635 | PurchaseCommon Stock | 800,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-19-011244 · rdgdoc.xml · nonDerivative · entry 1 SHANAHAN WILLIAM S · CIK 0001227259 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,105,460 F1 · price: The reported securities consist of 800,000 "Units" purchased by the reporting person for $0.25 per Unit. Each Unit consists of one share of Common Stock and a warrant to purchase one share of Common Stock. Read SEC document |
| December 21, 2018 Filed Dec 26, 2018 18:38 UTC | Cyclo Therapeutics, Inc. CTDH · Entity 82635 | PurchaseWarrant to Purchase Common Stock · Derivative | 153,846 | Not disclosed Strike: $0.65 | Not disclosed |
DisclosureSEC source: 0001437749-18-022629 · rdgdoc.xml · derivative · entry 2 SHANAHAN WILLIAM S · CIK 0001227259 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,846 Underlying: Common Stock · 153,846 shares Expires 2025-12-21 F1 · price: The reported securities consist of 153,846 "Units" purchased by the reporting person for $0.65 per Unit. Each Unit consists of one share of Common Stock and a warrant to purchase one share of Common Stock. Read SEC document |
| December 21, 2018 Filed Dec 26, 2018 18:38 UTC | Cyclo Therapeutics, Inc. CTDH · Entity 82635 | PurchaseCommon Stock | 153,846 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-18-022629 · rdgdoc.xml · nonDerivative · entry 1 SHANAHAN WILLIAM S · CIK 0001227259 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,305,460 F1 · price: The reported securities consist of 153,846 "Units" purchased by the reporting person for $0.65 per Unit. Each Unit consists of one share of Common Stock and a warrant to purchase one share of Common Stock. Read SEC document |
| May 23, 2018 Filed Jun 28, 2018 16:03 UTC | Cyclo Therapeutics, Inc. CTDH · Entity 82635 | ConversionSeries B Convertible Preferred Stock · Derivative | 1,000 | Not disclosed Strike: $0.25 | Not disclosed |
DisclosureSEC source: 0001437749-18-012614 · rdgdoc.xml · derivative · entry 2 SHANAHAN WILLIAM S · CIK 0001227259 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 400,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Reflects the automatic conversion of Series B Convertible Preferred Stock ("Series B Preferred") into Common Stock upon the filing of Articles of Amendment to the Issuer's Articles of Incorporation increasing the Issuer's authorized shares of Common Stock. The conversion is an exempt transaction pursuant to Rule 16b-7 under the Securities Exchange Act of 1934, as amended. F2 · price: The Series B Preferred were included in "Units" purchased by the reporting person for $100 per Unit. Each Unit consisted of one share of Series B Preferred convertible into 400 shares of Common Stock and one warrant to purchase 400 shares of Common Stock. F1 · derivative.exercise_date: Reflects the automatic conversion of Series B Convertible Preferred Stock ("Series B Preferred") into Common Stock upon the filing of Articles of Amendment to the Issuer's Articles of Incorporation increasing the Issuer's authorized shares of Common Stock. The conversion is an exempt transaction pursuant to Rule 16b-7 under the Securities Exchange Act of 1934, as amended. F1 · derivative.expiration_date: Reflects the automatic conversion of Series B Convertible Preferred Stock ("Series B Preferred") into Common Stock upon the filing of Articles of Amendment to the Issuer's Articles of Incorporation increasing the Issuer's authorized shares of Common Stock. The conversion is an exempt transaction pursuant to Rule 16b-7 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| May 23, 2018 Filed Jun 28, 2018 16:03 UTC | Cyclo Therapeutics, Inc. CTDH · Entity 82635 | ConversionCommon Stock | 400,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-18-012614 · rdgdoc.xml · nonDerivative · entry 1 SHANAHAN WILLIAM S · CIK 0001227259 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,151,614 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Reflects the automatic conversion of Series B Convertible Preferred Stock ("Series B Preferred") into Common Stock upon the filing of Articles of Amendment to the Issuer's Articles of Incorporation increasing the Issuer's authorized shares of Common Stock. The conversion is an exempt transaction pursuant to Rule 16b-7 under the Securities Exchange Act of 1934, as amended. F2 · price: The Series B Preferred were included in "Units" purchased by the reporting person for $100 per Unit. Each Unit consisted of one share of Series B Preferred convertible into 400 shares of Common Stock and one warrant to purchase 400 shares of Common Stock. Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 16:28 UTC | Cyclo Therapeutics, Inc. CTDH · Entity 82635 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-18-001674 · rdgdoc.xml · nonDerivative · entry 1 SHANAHAN WILLIAM S · CIK 0001227259 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 751,614 Read SEC document |
| October 18, 2017 Filed Oct 19, 2017 16:01 UTC | Cyclo Therapeutics, Inc. CTDH · Entity 82635 | PurchaseWarrant to Purchase Common Stock · Derivative | 400,000 | Not disclosed Strike: $0.25 | Not disclosed |
DisclosureSEC source: 0001437749-17-017324 · rdgdoc.xml · derivative · entry 2 SHANAHAN WILLIAM S · CIK 0001227259 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2024-10-18 F2 · price: The reported securities consist of 1,000 "Units" purchased by the reporting person for $100 per Unit. Each Unit consists of one share of Series B Preferred and warrants to purchase 400 shares of Common Stock. Read SEC document |
| October 18, 2017 Filed Oct 19, 2017 16:01 UTC | Cyclo Therapeutics, Inc. CTDH · Entity 82635 | PurchaseSeries B Convertible Preferred Stock · Derivative | 1,000 | Not disclosed Strike: $0.25 | Not disclosed |
DisclosureSEC source: 0001437749-17-017324 · rdgdoc.xml · derivative · entry 1 SHANAHAN WILLIAM S · CIK 0001227259 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 Underlying: Common Stock · 400,000 shares Expires not disclosed F2 · price: The reported securities consist of 1,000 "Units" purchased by the reporting person for $100 per Unit. Each Unit consists of one share of Series B Preferred and warrants to purchase 400 shares of Common Stock. F1 · derivative.exercise_date: The Series B Convertible Preferred Stock ("Series B Preferred") will automatically convert into Common Stock on the date the Issuer effects an increase of its authorized shares of Common Stock and/or a reverse stock split so that it has a sufficient number of authorized and unissued shares of Common Stock to permit the conversion or exercise, as applicable of all outstanding shares of Series B Preferred, warrants, options and other convertible securities of the Issuer. F1 · derivative.expiration_date: The Series B Convertible Preferred Stock ("Series B Preferred") will automatically convert into Common Stock on the date the Issuer effects an increase of its authorized shares of Common Stock and/or a reverse stock split so that it has a sufficient number of authorized and unissued shares of Common Stock to permit the conversion or exercise, as applicable of all outstanding shares of Series B Preferred, warrants, options and other convertible securities of the Issuer. Read SEC document |
| March 31, 2017 Filed Apr 4, 2017 16:07 UTC | Cyclo Therapeutics, Inc. CTDH · Entity 82635 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-17-003312 · f4033117shanahan_ctdholdings.xml · nonDerivative · entry 1 SHANAHAN WILLIAM S · CIK 0001227259 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 731,614 Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 12:18 UTC | Cyclo Therapeutics, Inc. CTDH · Entity 82635 | PurchaseWarrant to Purchase Common Stock · Derivative | 285,714 | Not disclosed Strike: $0.35 | Not disclosed |
DisclosureSEC source: 0001213900-17-001795 · f4022317shanahan_ctdholding.xml · derivative · entry 2 SHANAHAN WILLIAM S · CIK 0001227259 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 285,714 Underlying: Common Stock · 285,714 shares Expires 2024-02-23 F1 · price: The reported securities consist of 285,714 "Units" purchased by the reporting person for $0.35 per Unit. Each Unit consists of one share of common stock and one warrant to purchase one share of common stock. Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 12:18 UTC | Cyclo Therapeutics, Inc. CTDH · Entity 82635 | PurchaseCommon Stock | 285,714 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-17-001795 · f4022317shanahan_ctdholding.xml · nonDerivative · entry 1 SHANAHAN WILLIAM S · CIK 0001227259 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 711,614 F1 · price: The reported securities consist of 285,714 "Units" purchased by the reporting person for $0.35 per Unit. Each Unit consists of one share of common stock and one warrant to purchase one share of common stock. Read SEC document |
| November 19, 2015 Filed Nov 23, 2015 22:56 UTC | VISA INC. V · Entity 495 | GrantRestricted Stock Units · Derivative | 2,246 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-15-032330 · form4.xml · derivative · entry 4 SHANAHAN WILLIAM S · CIK 0001227259 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,246 Underlying: Class A Common Stock · 2,246 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Visa Inc. common stock or a cash equivalent of its value. The restricted stock units vest on the first anniversary of the date of grant, subject to earlier vesting in full in limited circumstances specified in the award agreement. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Visa Inc. common stock or a cash equivalent of its value. The restricted stock units vest on the first anniversary of the date of grant, subject to earlier vesting in full in limited circumstances specified in the award agreement. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of Visa Inc. common stock or a cash equivalent of its value. The restricted stock units vest on the first anniversary of the date of grant, subject to earlier vesting in full in limited circumstances specified in the award agreement. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of Visa Inc. common stock or a cash equivalent of its value. The restricted stock units vest on the first anniversary of the date of grant, subject to earlier vesting in full in limited circumstances specified in the award agreement. Read SEC document |
| November 19, 2015 Filed Nov 23, 2015 22:56 UTC | VISA INC. V · Entity 495 | Exercise / conversionRestricted Stock Units · Derivative | 2,880 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-15-032330 · form4.xml · derivative · entry 3 SHANAHAN WILLIAM S · CIK 0001227259 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 2,880 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Visa Inc. common stock or a cash equivalent of its value. The restricted stock units vest on the first anniversary of the date of grant, subject to earlier vesting in full in limited circumstances specified in the award agreement. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Visa Inc. common stock or a cash equivalent of its value. The restricted stock units vest on the first anniversary of the date of grant, subject to earlier vesting in full in limited circumstances specified in the award agreement. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of Visa Inc. common stock or a cash equivalent of its value. The restricted stock units vest on the first anniversary of the date of grant, subject to earlier vesting in full in limited circumstances specified in the award agreement. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of Visa Inc. common stock or a cash equivalent of its value. The restricted stock units vest on the first anniversary of the date of grant, subject to earlier vesting in full in limited circumstances specified in the award agreement. Read SEC document |
| November 19, 2015 Filed Nov 23, 2015 22:56 UTC | VISA INC. V · Entity 495 | Exercise / conversionClass A Common Stock | 2,880 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-15-032330 · form4.xml · nonDerivative · entry 1 SHANAHAN WILLIAM S · CIK 0001227259 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,880 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Visa Inc. common stock or a cash equivalent of its value. The restricted stock units vest on the first anniversary of the date of grant, subject to earlier vesting in full in limited circumstances specified in the award agreement. Read SEC document |
| November 19, 2014 Filed Nov 22, 2014 00:02 UTC | VISA INC. V · Entity 495 | GrantRestricted Stock Units · Derivative | 720 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-14-033180 · form4.xml · derivative · entry 4 SHANAHAN WILLIAM S · CIK 0001227259 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 720 Underlying: Common Stock · 720 shares Expires 2024-11-19 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Visa Inc. common stock or a cash equivalent of its value. The restricted stock units vest on the first anniversary of the date of grant, subject to earlier vesting in full in limited circumstances specified in the award agreement. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Visa Inc. common stock or a cash equivalent of its value. The restricted stock units vest on the first anniversary of the date of grant, subject to earlier vesting in full in limited circumstances specified in the award agreement. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of Visa Inc. common stock or a cash equivalent of its value. The restricted stock units vest on the first anniversary of the date of grant, subject to earlier vesting in full in limited circumstances specified in the award agreement. Read SEC document |
| November 19, 2014 Filed Nov 22, 2014 00:02 UTC | VISA INC. V · Entity 495 | Exercise / conversionRestricted Stock Units · Derivative | 887 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-14-033180 · form4.xml · derivative · entry 3 SHANAHAN WILLIAM S · CIK 0001227259 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 887 shares Expires 2023-11-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Visa Inc. common stock or a cash equivalent of its value. The restricted stock units vest on the first anniversary of the date of grant, subject to earlier vesting in full in limited circumstances specified in the award agreement. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Visa Inc. common stock or a cash equivalent of its value. The restricted stock units vest on the first anniversary of the date of grant, subject to earlier vesting in full in limited circumstances specified in the award agreement. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of Visa Inc. common stock or a cash equivalent of its value. The restricted stock units vest on the first anniversary of the date of grant, subject to earlier vesting in full in limited circumstances specified in the award agreement. Read SEC document |
| November 19, 2014 Filed Nov 22, 2014 00:02 UTC | VISA INC. V · Entity 495 | Exercise / conversionClass A Common Stock | 887 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-14-033180 · form4.xml · nonDerivative · entry 1 SHANAHAN WILLIAM S · CIK 0001227259 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 887 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Visa Inc. common stock or a cash equivalent of its value. The restricted stock units vest on the first anniversary of the date of grant, subject to earlier vesting in full in limited circumstances specified in the award agreement. Read SEC document |
| November 19, 2013 Filed Nov 21, 2013 23:08 UTC | VISA INC. V · Entity 495 | GrantRestricted Stock Units · Derivative | 887 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-13-032521 · form4.xml · derivative · entry 3 SHANAHAN WILLIAM S · CIK 0001227259 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 887 Underlying: Common Stock · 887 shares Expires 2023-11-19 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Visa Inc. common stock or a cash equivalent of its value. The restricted stock vests on the first anniversary of the date of grant, subject to earlier vesting in full in limited circumstances specified in the award agreement. F2 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of Visa Inc. common stock or a cash equivalent of its value. The restricted stock vests on the first anniversary of the date of grant, subject to earlier vesting in full in limited circumstances specified in the award agreement. Read SEC document |
| November 19, 2012 Filed Nov 22, 2012 01:06 UTC | VISA INC. V · Entity 495 | GrantClass A Common Stock | 1,202 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-12-031890 · form4.xml · nonDerivative · entry 1 SHANAHAN WILLIAM S · CIK 0001227259 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,091 F1 · shares: Represents restricted stock granted pursuant to the Visa Inc. 2007 Equity Incentive Compensation Plan. The restricted stock vests on the first anniversary of the date of grant, subject to earlier vesting in full in limited circumstances specified in the award agreement. Read SEC document |
| May 24, 2012 Filed May 25, 2012 21:03 UTC | VISA INC. V · Entity 495 | SaleClass A Common Stock | 27,000 | $119.14 | $3,216,780.00 |
DisclosureSEC source: 0001127602-12-018284 · form4.xml · nonDerivative · entry 1 SHANAHAN WILLIAM S · CIK 0001227259 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · William Shanahan Revocable Trust Disclosed balance after: 38,417 F1 · price: The price reported in column 4 is a weighted average price. These shares were disposed of in multiple transactions at prices ranging from $118.77-$119.48, inclusive. The reporting person undertakes to provide to Visa Inc., any security holder of Visa Inc., or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares disposed of at each separate price within the ranges set forth in this Form 4. F2 · balance_after: Since the date of the reporting person's last ownership report, 10,705 shares which were previously held directly were transferred to the William S Shanahan Revocable Trust, of which Mr. Shanahan is the sole trustee and beneficiary. Read SEC document |
| February 10, 2012 Filed Feb 14, 2012 22:48 UTC | VISA INC. V · Entity 495 | GiftClass A Common Stock | 5,288 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-12-005972 · form4.xml · nonDerivative · entry 1 SHANAHAN WILLIAM S · CIK 0001227259 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · William Shanahan Revocable Trust Disclosed balance after: 54,712 Read SEC document |
| November 05, 2011 Filed Nov 9, 2011 02:23 UTC | VISA INC. V · Entity 495 | GrantClass A Common Stock | 1,889 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-11-029044 · form4.xml · nonDerivative · entry 1 SHANAHAN WILLIAM S · CIK 0001227259 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,594 F1 · shares: Represents restricted stock granted pursuant to the Visa Inc. 2007 Equity Incentive Compensation Plan. The restricted stock vests on the first anniversary of the date of grant, subject to earlier vesting in full in limited circumstances specified in the award agreement. Read SEC document |
| November 05, 2010 Filed Nov 10, 2010 01:06 UTC | VISA INC. V · Entity 495 | GrantClass A Common Stock | 2,030 | $0.00 | $0.00 |
DisclosureSEC source: 0001181431-10-054556 · rrd290048.xml · nonDerivative · entry 1 SHANAHAN WILLIAM S · CIK 0001227259 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,705 F1 · shares: Represents restricted stock granted pursuant to the Visa Inc. 2007 Equity Incentive Compensation Plan. The restricted stock vests on the first anniversary of the date of grant, subject to earlier vesting in full in limited circumstances specified in the award agreement. Read SEC document |
| September 01, 2010 Filed Sep 1, 2010 22:10 UTC | VISA INC. V · Entity 495 | SaleClass A Common Stock | 65,000 | $70.10 | $4,556,448.00 |
DisclosureSEC source: 0001181431-10-045155 · rrd285489.xml · nonDerivative · entry 1 SHANAHAN WILLIAM S · CIK 0001227259 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · William Shanahan Revocable Trust Disclosed balance after: 60,000 F1 · price: The price reported in column 4 is a weighted average price. These shares were disposed of in multiple transactions at prices ranging from $70.01-$70.13, inclusive. The reporting person undertakes to provide to Visa Inc., any security holder of Visa Inc., or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares disposed of at each separate price within the ranges set forth in this Form 4. Read SEC document |
| November 05, 2009 Filed Nov 10, 2009 01:06 UTC | VISA INC. V · Entity 495 | GrantClass A Common Stock | 2,035 | $0.00 | $0.00 |
DisclosureSEC source: 0001181431-09-050699 · rrd256536.xml · nonDerivative · entry 1 SHANAHAN WILLIAM S · CIK 0001227259 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,675 F1 · shares: Represents restricted stock granted pursuant to the Visa Inc. 2007 Equity Incentive Compensation Plan. The restricted stock vests on the first anniversary of the date of grant, subject to earlier vesting in full in limited circumstances specified in the award agreement. Read SEC document |
| December 16, 2008 Filed Dec 18, 2008 18:21 UTC | VISA INC. V · Entity 495 | GrantClass A Common Stock | 2,958 | $0.00 | $0.00 |
DisclosureSEC source: 0001181431-08-068138 · rrd226735.xml · nonDerivative · entry 1 SHANAHAN WILLIAM S · CIK 0001227259 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,640 F1 · shares: Represents restricted stock granted pursuant to the Visa Inc. 2007 Equity Incentive Compensation Plan. The restricted stock vests on the first anniversary of the date of grant, subject to earlier vesting in full in limited circumstances specified in the award agreement. Read SEC document |
| March 25, 2008 Filed Mar 25, 2008 20:55 UTC | VISA INC. V · Entity 495 | PurchaseClass A Common Stock | 125,000 | $44.00 | $5,500,000.00 |
DisclosureSEC source: 0001181431-08-021126 · rrd200853.xml · nonDerivative · entry 1 SHANAHAN WILLIAM S · CIK 0001227259 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,682 F1 · shares: Represents shares purchased pursuant to Visa Inc.'s Directed Share Program upon the closing of its initial public offering. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.